Rethinking Diabetes Care

Key Insights into the Expanding CGM Market 

Diabetes is one of the most pressing global health challenges, affecting an estimated 537 million adults worldwide in 2021—a number projected to rise to 783 million by 2045. As the complexity of diabetes management grows, the need for continuous, real-time glucose monitoring has never been more critical. Continuous Glucose Monitors (CGMs) address these challenges by providing patients with timely insights into their glucose levels, enabling more informed decision-making and better health outcomes.

Valued at $11.63 billion in 2024, the CGM market is projected to reach $21 billion by 2029, driven by technological advancements, greater accessibility, and the growing availability of non-invasive, over-the-counter (OTC) solutions.

Key Factors Shaping The Market:

• Innovations in CGM technology, including non-invasive glucose monitoring and seamless integration with mobile applications, are improving the convenience, accuracy, and accessibility of diabetes care.
• The emergence of OTC CGM products is broadening access to diabetes care, particularly for non-insulin-dependent patients and wellness-focused individuals, creating a significant shift in the market.
• The CGM market is characterized by a surge in patent filings, as companies race to protect their innovations and secure leadership positions. Ongoing litigation trends further highlight the high stakes in this rapidly evolving market.